An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK

INTRODUCTION: Voretigene neparvovec (VN) is a gene therapy and the first approved pharmacological treatment for biallelic RPE65-mediated inherited retinal dystrophies (IRD), a rare condition that starts in early life and causes vision to progressively deteriorate towards complete blindness. In a pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Viriato, Daniel, Bennett, Natalie, Sidhu, Raisa, Hancock, Elizabeth, Lomax, Hannah, Trueman, David, MacLaren, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089725/
https://www.ncbi.nlm.nih.gov/pubmed/32034665
http://dx.doi.org/10.1007/s12325-020-01243-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089725/
https://www.ncbi.nlm.nih.gov/pubmed/32034665
http://dx.doi.org/10.1007/s12325-020-01243-y

Ejemplares similares